NSIM
CLDX icon

North Star Investment Management’s Celldex Therapeutics CLDX Stock Holding History

North Star Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-800
Closed -$22K – 1215
2023
Q3 		$22K Hold
800
– – ﹤0.01% 717
2023
Q2 		$27.1K Hold
800
– – ﹤0.01% 700
2023
Q1 		$28.8K Hold
800
– – ﹤0.01% 709
2022
Q4 		$35.7K Hold
800
– – ﹤0.01% 653
2022
Q3 		$22K Hold
800
– – ﹤0.01% 679
2022
Q2 		$22K Hold
800
– – ﹤0.01% 692
2022
Q1 		$27K Hold
800
– – ﹤0.01% 694
2021
Q4 		$31K Hold
800
– – ﹤0.01% 705
2021
Q3 		$43K Buy
+800
New +$37.5K ﹤0.01% 614

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

North Star Investment Management's CLDX Position: Q4 2023 in Review

North Star Investment Management sold out of Celldex Therapeutics (CLDX) in Q4 2023, closing a stake of 800 shares — an estimated $22K sold.

North Star Investment Management first reported a position in CLDX in Q3 2021 and held it in 9 quarters. The position peaked at $43K in Q3 2021. 164 funds tracked by Wall St. Rank hold CLDX as of Q4 2023.

  • North Star Investment Management reported no remaining Celldex Therapeutics position as of Q4 2023 after selling out during the quarter.
  • North Star Investment Management sold 800 Celldex Therapeutics shares in Q4 2023, an estimated $22K.
  • North Star Investment Management first reported a position in Celldex Therapeutics in Q3 2021 and held it in 9 quarters.
  • North Star Investment Management's Celldex Therapeutics position peaked at $43K in Q3 2021.
  • 164 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2023.

Based on North Star Investment Management's 13F filing for Q4 2023, filed 10 Jan 2024.